In-licensing of BGB324 from Rigel
PharmaVenture Client Bergen Bio Licenses R428.
![12_Bergen_Rigel](https://www.pharmaventures.com/wp-content/uploads/2020/11/12_Bergen_Rigel.png)
Oxford, UK
PharmaVentures Client BergenBio entered into an agreement for Rigel’s preclinical candidate, R428 (now referred to as BGB324), an Axl kinase inhibitor for oncology.
For press enquiries, please contact:
Lisa Holloway
Senior Marketing Manager
PharmaVentures Ltd
+44 (0) 1865 332700